These research directions hold the promise of improving the treatment outcomes and prognosis for colorectal cancer patients.The current biomarkers employed by clinicians to forecast the prognosis and therapeutic responsiveness of CRC patients, such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), exhibit relatively limited sensitivity and specificity (12). The gene discussed is CEACAM5; the disease is colorectal cancer.